Christina Furebring

This inventor holds 19 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Antibody Engineering. Top assignees: Alligator Bioscience Ab, Aptevo Research and Development LLC, Aptevo Reserch and Development LLC. Active years: 2005-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christina Furebring. Retrieved from https://idiyas.com/inventor/christina-furebring

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 5)

% Patents Active = 57.9

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 6 (Patent Applications = 11)

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 26(Granted Patents)

Company Filing History:

19 out of 37

Alligator Bioscience Ab

patents

2 out of 12

Aptevo Research and Development LLC

patents

1 out of 1

Aptevo Reserch and Development LLC

patent

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

Areas of Expertise:

Anti-CD137 Antibodies

Bispecific Polypeptides

Antigen Binding Proteins

Oncofetal Antigens

CD86 Variants

Molecular Evolution

Protein Function

Polypeptides

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12509526 - NOVEL ANTI-CD137 ANTIBODIES AND USES THEREOF (2025-12-30),

2. 12173082 - Bispecific polypeptides against CD137 (2024-12-24),

3. 11780928 - Polypeptides (2023-10-10),

4. 11725060 - Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods (2023-08-15),

5. 11535678 - Anti-CD137 antibodies and uses thereof (2022-12-27),

6. 11312786 - Oncofetal antigen binding proteins and related compositions and methods (2022-04-26),

7. 11008396 - Polypeptides (2021-05-18),

8. 10774150 - Polypeptides (2020-09-15),

9. 10689454 - Anti-CD137 antibodies and uses thereof (2020-06-23),

10. 10239949 - Oncofetal antigen binding proteins and related compositions and methods (2019-03-26),

11. 9834589 - CD86 variants with improved affinity for CTLA-4 (2017-12-05),

12. 8552149 - Polypeptides and use thereof (2013-10-08),

13. 8173774 - Polypeptides and use thereof (2012-05-08),

14. 7816085 - Method for in vitro molecular evolution of protein function (2010-10-19),

15. 7563578 - Method for in vitro molecular evolution of protein function (2009-07-21),

Title: **Christina Furebring: Pioneering Innovations in Bispecific Polypeptides**

Introduction

Christina Furebring, an accomplished inventor based in Lund, Sweden, has made significant contributions to the field of biomedicine. With a remarkable portfolio of 18 patents, she stands out for her innovative work in the development of bispecific polypeptides.

Latest Patents

Among Christina's notable patents is the invention of bispecific polypeptides against CD137. This invention provides novel bispecific polypeptides that feature a first binding domain, designated B1, capable of specifically binding to CD137, alongside a second binding domain, designated B2, which targets a tumour cell-associated antigen. The patent also encompasses pharmaceutical compositions of these polypeptides and their medical applications. Another significant patent involves bispecific polypeptides, including bispecific antibodies, that comprise a first binding domain specifically binding to one T cell target and a second binding domain for a different T cell target. This invention further details the compositions of these bispecific polypeptides and outlines methods and therapeutic uses.

Career Highlights

Throughout her career, Christina has collaborated with leading organizations such as Alligator Bioscience AB and Aptevo Research and Development LLC. Her work at these companies has significantly advanced the development of innovative therapeutics aimed at improving cancer treatments.

Collaborations

Christina has collaborated with notable peers in her field, including Peter Ellmark and Sara Fritzell. These collaborations have not only enriched her research but have also contributed to the broader scientific community's understanding of bispecific polypeptides.

Conclusion

Christina Furebring exemplifies the spirit of innovation in the field of biomedicine. Through her pioneering patents and collaborative efforts, she continues to influence advancements in medical science, showcasing the important role of inventors in the ongoing quest for effective therapies.

Profile summary based on public USPTO records.